Trial tests gentler rejection prevention for High-Risk kidney transplants
NCT ID NCT02377193
Summary
This study compared two different drug combinations used right after a kidney transplant to prevent the body from rejecting the new organ. It focused on patients at high risk for rejection because their immune systems were already 'sensitized' to foreign tissue. The goal was to see if a newer, potentially gentler drug (basiliximab) worked as well as an older, stronger one (ATG) at preventing rejection while causing fewer side effects like infections.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UHToulouse
Toulouse, France, 31059, France
Conditions
Explore the condition pages connected to this study.